58 results
8-K
EX-1.1
LRMR
Larimar Therapeutics Inc
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
HIPAA, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679), and other similar state privacy laws (collectively, the “Privacy Laws … Security Council, the European Union, His Majesty’s Treasury-UK, or other relevant sanctions authority (collectively, “Sanctions”) and the Company
424B5
LRMR
Larimar Therapeutics Inc
14 Feb 24
Prospectus supplement for primary offering
5:08pm
and the expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union
424B5
LRMR
Larimar Therapeutics Inc
13 Feb 24
Prospectus supplement for primary offering
4:46pm
law by virtue of the European Union (Withdrawal) Act 2018.
Notice to Prospective Investors in Canada
The securities may be sold only to purchasers
8-K
EX-1.1
ud1 0zbmd
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
424B5
pkygv7 rzcbb
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-10.1
lh2ppp2py
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
xy3340 8l6z7c8g
11 Aug 20
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
7:38am
8-K/A
EX-99.2
cd5jvs g1
26 Jun 20
Other Events
5:08pm
8-K
EX-99.1
x8yh0p
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
8-K
EX-10.1
yrgx9b he0
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
DEFM14A
sd3qs0kbw5i8tit
29 Apr 20
Proxy related to merger
3:20pm
PRER14A
tir3p16661n
10 Apr 20
Preliminary revised proxy
4:38pm